<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35727341</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>21</Day></PubDate></JournalIssue><Title>Cellular and molecular life sciences : CMLS</Title><ISOAbbreviation>Cell Mol Life Sci</ISOAbbreviation></Journal><ArticleTitle>Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases.</ArticleTitle><Pagination><StartPage>374</StartPage><MedlinePgn>374</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">374</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-022-04408-w</ELocationID><Abstract><AbstractText>Myostatin is a negative regulator of skeletal muscle growth secreted by skeletal myocytes. In the past years, myostatin inhibition sparked interest among the scientific community for its potential to enhance muscle growth and to reduce, or even prevent, muscle atrophy. These characteristics make it a promising target for the treatment of muscle atrophy in motor neuron diseases, namely, amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), which are rare neurological diseases, whereby the degeneration of motor neurons leads to progressive muscle loss and paralysis. These diseases carry a huge burden of morbidity and mortality but, despite this unfavorable scenario, several therapeutic advancements have been made in the past years. Indeed, a number of different curative therapies for SMA have been approved, leading to a revolution in the life expectancy and outcomes of SMA patients. Similarly, tofersen, an antisense oligonucleotide, is now undergoing clinical trial phase for use in ALS patients carrying the SOD1 mutation. However, these therapies are not able to completely halt or reverse progression of muscle damage. Recently, a trial evaluating apitegromab, a myostatin inhibitor, in SMA patients was started, following positive results from preclinical studies. In this context, myostatin inhibition could represent a useful strategy to tackle motor symptoms in these patients. The aim of this review is to describe the myostatin pathway and its role in motor neuron diseases, and to summarize and critically discuss preclinical and clinical studies of myostatin inhibitors in SMA and ALS. Then, we will highlight promises and pitfalls related to the use of myostatin inhibitors in the human setting, to aid the scientific community in the development of future clinical trials.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Abati</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0797-8282</Identifier><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation (DEPT), Dino Ferrari Centre, Neuroscience Section, Neurology Unit, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, Department of Neuroscience, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Manini</LastName><ForeName>Arianna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation (DEPT), Dino Ferrari Centre, Neuroscience Section, Neurology Unit, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comi</LastName><ForeName>Giacomo Pietro</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation (DEPT), Dino Ferrari Centre, Neuroscience Section, Neurology Unit, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, Department of Neuroscience, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular and Rare Diseases Unit, Department of Neuroscience, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corti</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation (DEPT), Dino Ferrari Centre, Neuroscience Section, Neurology Unit, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy. stefania.corti@unimi.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, Department of Neuroscience, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. stefania.corti@unimi.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Ricerca corrente</GrantID><Agency>Ministero della Salute</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cell Mol Life Sci</MedlineTA><NlmUniqueID>9705402</NlmUniqueID><ISSNLinking>1420-682X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055435">Myostatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009133" MajorTopicYN="N">Muscular Atrophy</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="Y">Muscular Atrophy, Spinal</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055435" MajorTopicYN="N">Myostatin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Activin receptors, type II</Keyword><Keyword MajorTopicYN="N">Monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">Motor neuron diseases</Keyword><Keyword MajorTopicYN="N">Muscle atrophy</Keyword><Keyword MajorTopicYN="N">Myostatin</Keyword></KeywordList><CoiStatement>The authors declare no existing conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>21</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35727341</ArticleId><ArticleId IdType="pmc">PMC9213329</ArticleId><ArticleId IdType="doi">10.1007/s00018-022-04408-w</ArticleId><ArticleId IdType="pii">10.1007/s00018-022-04408-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>D&#x2019;Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71. doi: 10.1186/1750-1172-6-71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-6-71</ArticleId><ArticleId IdType="pmc">PMC3231874</ArticleId><ArticleId IdType="pubmed">22047105</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41:118&#x2013;130. doi: 10.1159/000351153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Abati E, Bresolin N, Comi G, Corti S. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS) Expert Opin Ther Targets. 2020;24:295&#x2013;310. doi: 10.1080/14728222.2020.1738390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2020.1738390</ArticleId><ArticleId IdType="pubmed">32125907</ArticleId></ArticleIdList></Reference><Reference><Citation>Abati E, Bresolin N, Comi G, Corti S. Advances, challenges, and perspectives in translational stem cell therapy for amyotrophic lateral sclerosis. Mol Neurobiol. 2019;56:6703&#x2013;6715. doi: 10.1007/s12035-019-1554-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1554-x</ArticleId><ArticleId IdType="pubmed">30911936</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMOA2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMOA2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaytow H, Huang YT, Gillingwater TH, Faller KME. The role of survival motor neuron protein (SMN) in protein homeostasis. Cell Mol Life Sci. 2018;75:3877&#x2013;3894. doi: 10.1007/S00018-018-2849-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00018-018-2849-1</ArticleId><ArticleId IdType="pmc">PMC6182345</ArticleId><ArticleId IdType="pubmed">29872871</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med. 2013;19:40&#x2013;50. doi: 10.1016/J.MOLMED.2012.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MOLMED.2012.11.002</ArticleId><ArticleId IdType="pubmed">23228902</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo CJJ, Darras BT. Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease. Pediatr Neurol. 2020;109:12&#x2013;19. doi: 10.1016/J.PEDIATRNEUROL.2020.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.PEDIATRNEUROL.2020.01.003</ArticleId><ArticleId IdType="pubmed">32409122</ArticleId></ArticleIdList></Reference><Reference><Citation>Abati E, Citterio G, Bresolin N, et al. Glial cells involvement in spinal muscular atrophy: could SMA be a neuroinflammatory disease? Neurobiol Dis. 2020 doi: 10.1016/J.NBD.2020.104870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NBD.2020.104870</ArticleId><ArticleId IdType="pubmed">32294521</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA. 1999;96:6307&#x2013;6311. doi: 10.1073/pnas.96.11.6307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.11.6307</ArticleId><ArticleId IdType="pmc">PMC26877</ArticleId><ArticleId IdType="pubmed">10339583</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh RN, Howell MD, Ottesen EW, Singh NN. Diverse role of survival motor neuron protein. Biochim Biophys Acta Gene Regul Mech. 2017;1860:299&#x2013;315. doi: 10.1016/J.BBAGRM.2016.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.BBAGRM.2016.12.008</ArticleId><ArticleId IdType="pmc">PMC5325804</ArticleId><ArticleId IdType="pubmed">28095296</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldk&#xf6;tter M, Schwarzer V, Wirth R, et al. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70:358&#x2013;368. doi: 10.1086/338627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/338627</ArticleId><ArticleId IdType="pmc">PMC419987</ArticleId><ArticleId IdType="pubmed">11791208</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11:443&#x2013;452. doi: 10.1016/S1474-4422(12)70061-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70061-3</ArticleId><ArticleId IdType="pubmed">22516079</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefebvre S, B&#xfc;rglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155&#x2013;165. doi: 10.1016/0092-8674(95)90460-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(95)90460-3</ArticleId><ArticleId IdType="pubmed">7813012</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33:831. doi: 10.1016/J.NCL.2015.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NCL.2015.07.004</ArticleId><ArticleId IdType="pmc">PMC4628728</ArticleId><ArticleId IdType="pubmed">26515624</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration . FDA approves first drug for spinal muscular atrophy. Rome: US Food and Drug Administration US Food and Drug Administration; 2016.</Citation></Reference><Reference><Citation>Hoy SM. Onasemnogene abeparvovec: first global approval. Drugs. 2019;79:1255&#x2013;1262. doi: 10.1007/s40265-019-01162-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-019-01162-5</ArticleId><ArticleId IdType="pubmed">31270752</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranello G, Darras BT, Day JW, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384:915&#x2013;923. doi: 10.1056/NEJMOA2009965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMOA2009965</ArticleId><ArticleId IdType="pubmed">33626251</ArticleId></ArticleIdList></Reference><Reference><Citation>McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387:83&#x2013;90. doi: 10.1038/387083A0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/387083A0</ArticleId><ArticleId IdType="pubmed">9139826</ArticleId></ArticleIdList></Reference><Reference><Citation>McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA. 1997;94:12457&#x2013;12461. doi: 10.1073/PNAS.94.23.12457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.94.23.12457</ArticleId><ArticleId IdType="pmc">PMC24998</ArticleId><ArticleId IdType="pubmed">9356471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kambadur R, Sharma M, Smith TPL, Bass JJ. Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res. 1997;7:910&#x2013;916. doi: 10.1101/GR.7.9.910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/GR.7.9.910</ArticleId><ArticleId IdType="pubmed">9314496</ArticleId></ArticleIdList></Reference><Reference><Citation>Clop A, Marcq F, Takeda H, et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet. 2006;38:813&#x2013;818. doi: 10.1038/NG1810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/NG1810</ArticleId><ArticleId IdType="pubmed">16751773</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher DS, Quignon P, Bustamante CD, et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet. 2007;3:779&#x2013;786. doi: 10.1371/JOURNAL.PGEN.0030079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PGEN.0030079</ArticleId><ArticleId IdType="pmc">PMC1877876</ArticleId><ArticleId IdType="pubmed">17530926</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv Q, Yuan L, Deng J, et al. Efficient generation of myostatin gene mutated rabbit by CRISPR/Cas9. Sci Rep. 2016 doi: 10.1038/SREP25029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/SREP25029</ArticleId><ArticleId IdType="pmc">PMC4844959</ArticleId><ArticleId IdType="pubmed">27113799</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu H, Cao Y, Qiu B, et al. Establishment and phenotypic analysis of an Mstn knockout rat. Biochem Biophys Res Commun. 2016;477:115&#x2013;122. doi: 10.1016/J.BBRC.2016.06.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.BBRC.2016.06.030</ArticleId><ArticleId IdType="pubmed">27289021</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Tang X, Xie Z, et al. CRISPR/Cas9-mediated knockout of myostatin in Chinese indigenous Erhualian pigs. Transgenic Res. 2017;26:799&#x2013;805. doi: 10.1007/S11248-017-0044-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S11248-017-0044-Z</ArticleId><ArticleId IdType="pubmed">28993973</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, Zhang T, Jiang L, 2018. Use of CRISPR/Cas9 technology efficiently targetted goat myostatin through zygotes microinjection resulting in double-muscled phenotype in goats. Biosci Rep.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20180742</ArticleId><ArticleId IdType="pmc">PMC6239268</ArticleId><ArticleId IdType="pubmed">30201688</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350:2682&#x2013;2688. doi: 10.1056/nejmoa040933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa040933</ArticleId><ArticleId IdType="pubmed">15215484</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundaresan NR, Saxena VK, Singh R, et al. Expression profile of myostatin mRNA during the embryonic organogenesis of domestic chicken (Gallus domesticus) Res Vet Sci. 2008;85:86&#x2013;91. doi: 10.1016/J.RVSC.2007.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.RVSC.2007.09.014</ArticleId><ArticleId IdType="pubmed">18037460</ArticleId></ArticleIdList></Reference><Reference><Citation>Takada H, Miwa Y, Sato I. Expression of myostatin in early postnatal mouse masseter and rectus femoris muscles. Histol Histopathol. 2015;30:1353&#x2013;1365. doi: 10.14670/HH-11-631.</Citation><ArticleIdList><ArticleId IdType="doi">10.14670/HH-11-631</ArticleId><ArticleId IdType="pubmed">25982068</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogaars WMH, Jaspers RT. Past, present, and future perspective of targeting myostatin and related signaling pathways to counteract muscle atrophy. Adv Exp Med Biol. 2018;1088:153&#x2013;206. doi: 10.1007/978-981-13-1435-3_8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-13-1435-3_8</ArticleId><ArticleId IdType="pubmed">30390252</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Huynh TV, Lee YS, et al. Role of satellite cells versus myofibers in muscle hypertrophy induced by inhibition of the myostatin/activin signaling pathway. Proc Natl Acad Sci USA. 2012 doi: 10.1073/PNAS.1206410109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.1206410109</ArticleId><ArticleId IdType="pmc">PMC3435227</ArticleId><ArticleId IdType="pubmed">22869749</ArticleId></ArticleIdList></Reference><Reference><Citation>Le VQ, Iacob RE, Tian Y, et al. Tolloid cleavage activates latent GDF8 by priming the pro-complex for dissociation. EMBO J. 2018;37:384&#x2013;397. doi: 10.15252/EMBJ.201797931.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/EMBJ.201797931</ArticleId><ArticleId IdType="pmc">PMC5793799</ArticleId><ArticleId IdType="pubmed">29343545</ArticleId></ArticleIdList></Reference><Reference><Citation>Han HQ, Zhou X, Mitch WE, Goldberg AL. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol. 2013;45:2333&#x2013;2347. doi: 10.1016/J.BIOCEL.2013.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.BIOCEL.2013.05.019</ArticleId><ArticleId IdType="pubmed">23721881</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfman NM, McPherron AC, Pappano WN, et al. Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci USA. 2003;100:15842&#x2013;15846. doi: 10.1073/PNAS.2534946100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.2534946100</ArticleId><ArticleId IdType="pmc">PMC307655</ArticleId><ArticleId IdType="pubmed">14671324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill JJ, Davies MV, Pearson AA, et al. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem. 2002;277:40735&#x2013;40741. doi: 10.1074/JBC.M206379200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/JBC.M206379200</ArticleId><ArticleId IdType="pubmed">12194980</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmers TA, Davies MV, Koniaris LG, et al. Induction of cachexia in mice by systemically administered myostatin. Science. 2002;296:1486&#x2013;1488. doi: 10.1126/SCIENCE.1069525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.1069525</ArticleId><ArticleId IdType="pubmed">12029139</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA. 2001;98:9306&#x2013;9311. doi: 10.1073/PNAS.151270098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.151270098</ArticleId><ArticleId IdType="pmc">PMC55416</ArticleId><ArticleId IdType="pubmed">11459935</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamer LW, Wolfman NM, Celeste AJ, et al. A novel BMP expressed in developing mouse limb, spinal cord, and tail bud is a potent mesoderm inducer in Xenopus embryos. Dev Biol. 1999;208:222&#x2013;232. doi: 10.1006/DBIO.1998.9191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/DBIO.1998.9191</ArticleId><ArticleId IdType="pubmed">10075854</ArticleId></ArticleIdList></Reference><Reference><Citation>Iemura SI, Yamamoto TS, Takagi C, et al. Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc Natl Acad Sci U S A. 1998;95:9337&#x2013;9342. doi: 10.1073/PNAS.95.16.9337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.95.16.9337</ArticleId><ArticleId IdType="pmc">PMC21339</ArticleId><ArticleId IdType="pubmed">9689081</ArticleId></ArticleIdList></Reference><Reference><Citation>Fainsod A, Dei&#xdf;ler K, Yelin R, et al. The dorsalizing and neural inducing gene follistatin is an antagonist of BMP-4. Mech Dev. 1997;63:39&#x2013;50. doi: 10.1016/S0925-4773(97)00673-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0925-4773(97)00673-4</ArticleId><ArticleId IdType="pubmed">9178255</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita H, ten Dijke P, Huylebroeck D, et al. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol. 1995;130:217&#x2013;226. doi: 10.1083/JCB.130.1.217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/JCB.130.1.217</ArticleId><ArticleId IdType="pmc">PMC2120513</ArticleId><ArticleId IdType="pubmed">7790373</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T, Takio K, Eto Y, et al. Activin-binding protein from rat ovary is follistatin. Science. 1990;247:836&#x2013;838. doi: 10.1126/SCIENCE.2106159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.2106159</ArticleId><ArticleId IdType="pubmed">2106159</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominique JE, G&#xe9;rard C. Myostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects. Exp Cell Res. 2006;312:2401&#x2013;2414. doi: 10.1016/J.YEXCR.2006.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.YEXCR.2006.04.012</ArticleId><ArticleId IdType="pubmed">16793037</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez J, Vernus B, Chelh I, et al. Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways. Cell Mol Life Sci. 2014;71:4361&#x2013;4371. doi: 10.1007/S00018-014-1689-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00018-014-1689-X</ArticleId><ArticleId IdType="pubmed">25080109</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumucio JP, Mendias CL. Atrogin-1, MuRF-1, and sarcopenia. Endocrine. 2013;43:12&#x2013;21. doi: 10.1007/S12020-012-9751-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S12020-012-9751-7</ArticleId><ArticleId IdType="pmc">PMC3586538</ArticleId><ArticleId IdType="pubmed">22815045</ArticleId></ArticleIdList></Reference><Reference><Citation>Sartori R, Milan G, Patron M, et al. Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Phys Cell Physiol. 2009;296:1248&#x2013;1257. doi: 10.1152/AJPCELL.00104.2009/SUPPL_FILE/SUPPLEMENTAL.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/AJPCELL.00104.2009/SUPPL_FILE/SUPPLEMENTAL</ArticleId><ArticleId IdType="pubmed">19357234</ArticleId></ArticleIdList></Reference><Reference><Citation>Latres E, Mastaitis J, Fury W, et al. Activin A more prominently regulates muscle mass in primates than does GDF8. Nat Commun. 2017 doi: 10.1038/NCOMMS15153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/NCOMMS15153</ArticleId><ArticleId IdType="pmc">PMC5414365</ArticleId><ArticleId IdType="pubmed">28452368</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JL, Walton KL, Hagg A, et al. Specific targeting of TGF-&#x3b2; family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc Natl Acad Sci USA. 2017;114:E5266&#x2013;E5275. doi: 10.1073/PNAS.1620013114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.1620013114</ArticleId><ArticleId IdType="pmc">PMC5495232</ArticleId><ArticleId IdType="pubmed">28607086</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ. Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS ONE. 2007 doi: 10.1371/JOURNAL.PONE.0000789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PONE.0000789</ArticleId><ArticleId IdType="pmc">PMC1949143</ArticleId><ArticleId IdType="pubmed">17726519</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Reed LA, Davies M, v, , et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A. 2005;102:18117&#x2013;18122. doi: 10.1073/PNAS.0505996102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.0505996102</ArticleId><ArticleId IdType="pmc">PMC1306793</ArticleId><ArticleId IdType="pubmed">16330774</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan X, Gaur U, Sun L, et al. The Growth Differentiation Factor 11 (GDF11) and Myostatin (MSTN) in tissue specific aging. Mech Ageing Dev. 2017;164:108&#x2013;112. doi: 10.1016/J.MAD.2017.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MAD.2017.04.009</ArticleId><ArticleId IdType="pubmed">28472635</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima M, Toyono T, Akamine A, Joyner A. Expression of growth/differentiation factor 11, a new member of the BMP/TGFbeta superfamily during mouse embryogenesis. Mech Dev. 1999;80:185&#x2013;189. doi: 10.1016/S0925-4773(98)00205-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0925-4773(98)00205-6</ArticleId><ArticleId IdType="pubmed">10072786</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer MJ, Atkinson EJ, Vanderboom PM, et al. Quantification of GDF11 and myostatin in human aging and cardiovascular disease. Cell Metab. 2016;23:1207&#x2013;1215. doi: 10.1016/J.CMET.2016.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CMET.2016.05.023</ArticleId><ArticleId IdType="pmc">PMC4913514</ArticleId><ArticleId IdType="pubmed">27304512</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergen HR, Farr JN, Vanderboom PM, et al. Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay. Skelet Muscle. 2015 doi: 10.1186/S13395-015-0047-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13395-015-0047-5</ArticleId><ArticleId IdType="pmc">PMC4502935</ArticleId><ArticleId IdType="pubmed">26180626</ArticleId></ArticleIdList></Reference><Reference><Citation>Fife E, Kostka J, Kroc &#x141;, et al. Relationship of muscle function to circulating myostatin, follistatin and GDF11 in older women and men. BMC Geriatr. 2018 doi: 10.1186/S12877-018-0888-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12877-018-0888-Y</ArticleId><ArticleId IdType="pmc">PMC6117873</ArticleId><ArticleId IdType="pubmed">30165829</ArticleId></ArticleIdList></Reference><Reference><Citation>Baccarelli A, Morpurgo PS, Corsi A, et al. Activin A serum levels and aging of the pituitary-gonadal axis: a cross-sectional study in middle-aged and elderly healthy subjects. Exp Gerontol. 2001;36:1403&#x2013;1412. doi: 10.1016/S0531-5565(01)00117-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0531-5565(01)00117-6</ArticleId><ArticleId IdType="pubmed">11602213</ArticleId></ArticleIdList></Reference><Reference><Citation>Willoughby DS, Wilborn CD. Estradiol in females may negate skeletal muscle myostatin mrna expression and serum myostatin propeptide levels after eccentric muscle contractions. J Sports Sci Med. 2006;5:672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861770</ArticleId><ArticleId IdType="pubmed">24357964</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakshman KM, Bhasin S, Corcoran C, et al. Measurement of myostatin concentrations in human serum: circulating concentrations in young and older men and effects of testosterone administration. Mol Cell Endocrinol. 2009;302:26&#x2013;32. doi: 10.1016/J.MCE.2008.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MCE.2008.12.019</ArticleId><ArticleId IdType="pubmed">19356623</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GI, Yoshino J, Reeds DN, et al. Testosterone and progesterone, but not estradiol, stimulate muscle protein synthesis in postmenopausal women. J Clin Endocrinol Metab. 2014;99:256. doi: 10.1210/JC.2013-2835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/JC.2013-2835</ArticleId><ArticleId IdType="pmc">PMC3879672</ArticleId><ArticleId IdType="pubmed">24203065</ArticleId></ArticleIdList></Reference><Reference><Citation>Salani S, Donadoni C, Rizzo F, et al. Generation of skeletal muscle cells from embryonic and induced pluripotent stem cells as an in vitro model and for therapy of muscular dystrophies. J Cell Mol Med. 2012;16:1353&#x2013;1364. doi: 10.1111/j.1582-4934.2011.01498.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2011.01498.x</ArticleId><ArticleId IdType="pmc">PMC3823206</ArticleId><ArticleId IdType="pubmed">22129481</ArticleId></ArticleIdList></Reference><Reference><Citation>Abati E, Sclarandi E, Comipietro, G, et al. Perspectives on hiPSC-derived muscle cells as drug discovery models for muscular dystrophies. Int J Mol Sci. 2021 doi: 10.3390/IJMS22179630.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/IJMS22179630</ArticleId><ArticleId IdType="pmc">PMC8431796</ArticleId><ArticleId IdType="pubmed">34502539</ArticleId></ArticleIdList></Reference><Reference><Citation>Joulia D, Bernardi H, Garandel V, et al. Mechanisms involved in the inhibition of myoblast proliferation and differentiation by myostatin. Exp Cell Res. 2003;286:263&#x2013;275. doi: 10.1016/S0014-4827(03)00074-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-4827(03)00074-0</ArticleId><ArticleId IdType="pubmed">12749855</ArticleId></ArticleIdList></Reference><Reference><Citation>Langley B, Thomas M, Bishop A, et al. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem. 2002;277:49831&#x2013;49840. doi: 10.1074/JBC.M204291200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/JBC.M204291200</ArticleId><ArticleId IdType="pubmed">12244043</ArticleId></ArticleIdList></Reference><Reference><Citation>Duli&#x107; V, Stein GH, Far DF, Reed SI. Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol Cell Biol. 1998;18:546&#x2013;557. doi: 10.1128/MCB.18.1.546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.18.1.546</ArticleId><ArticleId IdType="pmc">PMC121522</ArticleId><ArticleId IdType="pubmed">9418901</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas M, Langley B, Berry C, et al. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem. 2000;275:40235&#x2013;40243. doi: 10.1074/JBC.M004356200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/JBC.M004356200</ArticleId><ArticleId IdType="pubmed">10976104</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xed;os R, Carneiro I, Arce VM, Devesa J. Myostatin regulates cell survival during C2C12 myogenesis. Biochem Biophys Res Commun. 2001;280:561&#x2013;566. doi: 10.1006/BBRC.2000.4159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/BBRC.2000.4159</ArticleId><ArticleId IdType="pubmed">11162556</ArticleId></ArticleIdList></Reference><Reference><Citation>Camporez JPG, Petersen MC, Abudukadier A, et al. Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice. Proc Natl Acad Sci USA. 2016;113:2212&#x2013;2217. doi: 10.1073/PNAS.1525795113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.1525795113</ArticleId><ArticleId IdType="pmc">PMC4776508</ArticleId><ArticleId IdType="pubmed">26858428</ArticleId></ArticleIdList></Reference><Reference><Citation>Akpan I, Goncalves MD, Dhir R, et al. The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes (Lond) 2009;33:1265&#x2013;1273. doi: 10.1038/IJO.2009.162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/IJO.2009.162</ArticleId><ArticleId IdType="pmc">PMC2783781</ArticleId><ArticleId IdType="pubmed">19668253</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleasby ME, Jarmin S, Eilers W, et al. Local overexpression of the myostatin propeptide increases glucose transporter expression and enhances skeletal muscle glucose disposal. Am J Physiol Endocrinol Metab. 2014 doi: 10.1152/AJPENDO.00586.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/AJPENDO.00586.2013</ArticleId><ArticleId IdType="pmc">PMC3962614</ArticleId><ArticleId IdType="pubmed">24473441</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Jou W, Chanturiya T, et al. Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS ONE. 2009;4:4937. doi: 10.1371/JOURNAL.PONE.0004937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PONE.0004937</ArticleId><ArticleId IdType="pmc">PMC2654157</ArticleId><ArticleId IdType="pubmed">19295913</ArticleId></ArticleIdList></Reference><Reference><Citation>Koncarevic A, Cornwall-Brady M, Pullen A, et al. A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. Endocrinology. 2010;151:4289&#x2013;4300. doi: 10.1210/EN.2010-0134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/EN.2010-0134</ArticleId><ArticleId IdType="pubmed">20573726</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves MD, Pistilli EE, Balduzzi A, et al. Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition. PLoS ONE. 2010;5:1&#x2013;12. doi: 10.1371/JOURNAL.PONE.0012707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PONE.0012707</ArticleId><ArticleId IdType="pmc">PMC2939888</ArticleId><ArticleId IdType="pubmed">20856813</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Lehar A, Liu Y, et al. Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A. Proc Natl Acad Sci USA. 2020;117:30907&#x2013;30917. doi: 10.1073/PNAS.2019263117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.2019263117</ArticleId><ArticleId IdType="pmc">PMC7733802</ArticleId><ArticleId IdType="pubmed">33219121</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga M, Pervin S, Norris K, et al. Inhibition of in vitro and in vivo brown fat differentiation program by myostatin. Obesity (Silver Spring) 2013;21:1180&#x2013;1188. doi: 10.1002/OBY.20117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/OBY.20117</ArticleId><ArticleId IdType="pmc">PMC3735638</ArticleId><ArticleId IdType="pubmed">23868854</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier B, Murray B, Gutzwiller S, et al. Blockade of the activin receptor IIb activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism. Mol Cell Biol. 2012;32:2871&#x2013;2879. doi: 10.1128/MCB.06575-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.06575-11</ArticleId><ArticleId IdType="pmc">PMC3416189</ArticleId><ArticleId IdType="pubmed">22586266</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBrasseur NK, Schelhorn TM, Bernardo BL, et al. Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J Gerontol A Biol Sci Med Sci. 2009;64:940&#x2013;948. doi: 10.1093/GERONA/GLP068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/GERONA/GLP068</ArticleId><ArticleId IdType="pubmed">19483181</ArticleId></ArticleIdList></Reference><Reference><Citation>Artaza JN, Bhasin S, Magee TR, et al. Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1/2) mesenchymal multipotent cells. Endocrinology. 2005;146:3547&#x2013;3557. doi: 10.1210/EN.2005-0362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/EN.2005-0362</ArticleId><ArticleId IdType="pubmed">15878958</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebbapragada A, Benchabane H, Wrana JL, et al. Myostatin signals through a transforming growth factor &#x3b2;-like signaling pathway to block adipogenesis. Mol Cell Biol. 2003;23:7230. doi: 10.1128/MCB.23.20.7230-7242.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.23.20.7230-7242.2003</ArticleId><ArticleId IdType="pmc">PMC230332</ArticleId><ArticleId IdType="pubmed">14517293</ArticleId></ArticleIdList></Reference><Reference><Citation>Shtilbans A, Choi SG, Fowkes ME, et al. Differential gene expression in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12:250&#x2013;256. doi: 10.3109/17482968.2011.560946.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.560946</ArticleId><ArticleId IdType="pubmed">21375368</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat PF, Dubourg O, de Tapia M, et al. Muscle gene expression is a marker of amyotrophic lateral sclerosis severity. Neurodegener Dis. 2012;9:38&#x2013;52. doi: 10.1159/000329723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000329723</ArticleId><ArticleId IdType="pubmed">21934272</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira GP, Maximino JR, Maschietto M, et al. Early gene expression changes in skeletal muscle from SOD1(G93A) amyotrophic lateral sclerosis animal model. Cell Mol Neurobiol. 2014;34:451&#x2013;462. doi: 10.1007/S10571-014-0029-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S10571-014-0029-X</ArticleId><ArticleId IdType="pubmed">24442855</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez De Aguilar JL, Niederhauser-Wiederkehr C, Halter B, et al. Gene profiling of skeletal muscle in an amyotrophic lateral sclerosis mouse model. Physiol Genom. 2008;32:207&#x2013;218. doi: 10.1152/PHYSIOLGENOMICS.00017.2007/SUPPL_FILE/SUPPTEXTREVII.PDF.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/PHYSIOLGENOMICS.00017.2007/SUPPL_FILE/SUPPTEXTREVII.PDF</ArticleId><ArticleId IdType="pubmed">18000159</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasca E, Pegoraro V, Merico A, Angelini C. Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS. Clin Neuropathol. 2016;35:22&#x2013;30. doi: 10.5414/NP300889.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/NP300889</ArticleId><ArticleId IdType="pubmed">26588026</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariot V, Joubert R, Hourd&#xe9; C, et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun. 2017 doi: 10.1038/S41467-017-01486-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41467-017-01486-4</ArticleId><ArticleId IdType="pmc">PMC5709430</ArticleId><ArticleId IdType="pubmed">29192144</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijboom KE, Volpato V, Monz&#xf3;n-Sandoval J, et al. Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy. JCI Insight. 2021 doi: 10.1172/JCI.INSIGHT.149446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI.INSIGHT.149446</ArticleId><ArticleId IdType="pmc">PMC8410072</ArticleId><ArticleId IdType="pubmed">34236053</ArticleId></ArticleIdList></Reference><Reference><Citation>Burch PM, Pogoryelova O, Palandra J, et al. Reduced serum myostatin concentrations associated with genetic muscle disease progression. J Neurol. 2017;264:541&#x2013;553. doi: 10.1007/S00415-016-8379-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00415-016-8379-6</ArticleId><ArticleId IdType="pubmed">28074267</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose FF, Mattis VB, Rindt H, Lorson CL. Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Hum Mol Genet. 2009;18:997&#x2013;1005. doi: 10.1093/HMG/DDN426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/HMG/DDN426</ArticleId><ArticleId IdType="pmc">PMC2649020</ArticleId><ArticleId IdType="pubmed">19074460</ArticleId></ArticleIdList></Reference><Reference><Citation>Rindt H, Buckley DM, Vale SM, et al. Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy. Neuromuscul Disord. 2012;22:277&#x2013;285. doi: 10.1016/J.NMD.2011.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NMD.2011.10.012</ArticleId><ArticleId IdType="pubmed">22079083</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumner CJ, Wee CD, Warsing LC, et al. Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. Hum Mol Genet. 2009;18:3145&#x2013;3152. doi: 10.1093/HMG/DDP253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/HMG/DDP253</ArticleId><ArticleId IdType="pmc">PMC2733819</ArticleId><ArticleId IdType="pubmed">19477958</ArticleId></ArticleIdList></Reference><Reference><Citation>Shababi M, Habibi J, Yang HT, et al. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum Mol Genet. 2010;19:4059&#x2013;4071. doi: 10.1093/HMG/DDQ329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/HMG/DDQ329</ArticleId><ArticleId IdType="pubmed">20696672</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z, Ling KKY, Zhao X, et al. Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset. Hum Mol Genet. 2016;25:964&#x2013;975. doi: 10.1093/HMG/DDV629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/HMG/DDV629</ArticleId><ArticleId IdType="pubmed">26758873</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Hammers DW, Barton ER, Sweeney HL. Activin receptor type IIB inhibition improves muscle phenotype and function in a mouse model of spinal muscular atrophy. PLoS ONE. 2016 doi: 10.1371/JOURNAL.PONE.0166803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PONE.0166803</ArticleId><ArticleId IdType="pmc">PMC5117715</ArticleId><ArticleId IdType="pubmed">27870893</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Meng J, Malerba A, et al. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. J Cachexia Sarcopenia Muscle. 2020;11:768&#x2013;782. doi: 10.1002/JCSM.12542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JCSM.12542</ArticleId><ArticleId IdType="pmc">PMC7296258</ArticleId><ArticleId IdType="pubmed">32031328</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirruccello-Straub M, Jackson J, Wawersik S, et al. Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci Rep. 2018 doi: 10.1038/S41598-018-20524-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41598-018-20524-9</ArticleId><ArticleId IdType="pmc">PMC5797207</ArticleId><ArticleId IdType="pubmed">29396542</ArticleId></ArticleIdList></Reference><Reference><Citation>Long KK, O&#x2019;Shea KM, Khairallah RJ, et al. Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy. Hum Mol Genet. 2019;28:1076&#x2013;1089. doi: 10.1093/HMG/DDY382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/HMG/DDY382</ArticleId><ArticleId IdType="pmc">PMC6423420</ArticleId><ArticleId IdType="pubmed">30481286</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzbaur ELF, Howland DS, Weber N, et al. Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol Dis. 2006;23:697&#x2013;707. doi: 10.1016/J.NBD.2006.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NBD.2006.05.009</ArticleId><ArticleId IdType="pubmed">16837207</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Kim SH, Yamanaka K, et al. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2006;103:19546&#x2013;19551. doi: 10.1073/PNAS.0609411103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.0609411103</ArticleId><ArticleId IdType="pmc">PMC1748262</ArticleId><ArticleId IdType="pubmed">17164329</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison BM, Lachey JL, Warsing LC, et al. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2009;217:258&#x2013;268. doi: 10.1016/J.EXPNEUROL.2009.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.EXPNEUROL.2009.02.017</ArticleId><ArticleId IdType="pubmed">19285073</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Fredericks M, Cannell M, et al. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders. J Clin Invest. 2021 doi: 10.1172/JCI138634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138634</ArticleId><ArticleId IdType="pmc">PMC7880416</ArticleId><ArticleId IdType="pubmed">33586684</ArticleId></ArticleIdList></Reference><Reference><Citation>Golan T, Geva R, Richards D, et al. LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial. J Cachexia Sarcopenia Muscle. 2018;9:871&#x2013;879. doi: 10.1002/JCSM.12331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JCSM.12331</ArticleId><ArticleId IdType="pmc">PMC6204586</ArticleId><ArticleId IdType="pubmed">30051975</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63:561&#x2013;571. doi: 10.1002/ANA.21338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ANA.21338</ArticleId><ArticleId IdType="pubmed">18335515</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner KR, Abdel-Hamid HZ, Mah JK, et al. Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscul Disord. 2020;30:492&#x2013;502. doi: 10.1016/J.NMD.2020.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NMD.2020.05.002</ArticleId><ArticleId IdType="pubmed">32522498</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker C, Lord SR, Studenski SA, et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2015;3:948&#x2013;957. doi: 10.1016/S2213-8587(15)00298-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(15)00298-3</ArticleId><ArticleId IdType="pubmed">26516121</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooks D, Praestgaard J, Hariry S, et al. Treatment of sarcopenia with bimagrumab: results from a phase II, randomized, controlled, proof-of-concept study. J Am Geriatr Soc. 2017;65:1988&#x2013;1995. doi: 10.1111/JGS.14927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/JGS.14927</ArticleId><ArticleId IdType="pubmed">28653345</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna MG, Badrising UA, Benveniste O, et al. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2019;18:834&#x2013;844. doi: 10.1016/S1474-4422(19)30200-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30200-5</ArticleId><ArticleId IdType="pubmed">31397289</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodhouse L, Gandhi R, Warden SJ, et al. A Phase 2 randomized study investigating the efficacy and safety of myostatin antibody LY2495655 versus placebo in patients undergoing elective total hip arthroplasty. J Frailty Aging. 2016;5:62&#x2013;70. doi: 10.14283/JFA.2016.81.</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/JFA.2016.81</ArticleId><ArticleId IdType="pubmed">26980371</ArticleId></ArticleIdList></Reference><Reference><Citation>Heymsfield SB, Coleman LA, Miller R, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021 doi: 10.1001/JAMANETWORKOPEN.2020.33457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMANETWORKOPEN.2020.33457</ArticleId><ArticleId IdType="pmc">PMC7807292</ArticleId><ArticleId IdType="pubmed">33439265</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett D, Bilic S, Chyung Y, et al. A randomized phase 1 safety, pharmacokinetic and pharmacodynamic study of the novel myostatin inhibitor apitegromab (SRK-015): a potential treatment for spinal muscular atrophy. Adv Ther. 2021;38:3203&#x2013;3222. doi: 10.1007/S12325-021-01757-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S12325-021-01757-Z</ArticleId><ArticleId IdType="pmc">PMC8189951</ArticleId><ArticleId IdType="pubmed">33963971</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner KR, Abdel-Hamid HZ, Mah JK, et al. Corrigendum to Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscul Disord. 2021;31:167&#x2013;168. doi: 10.1016/J.NMD.2021.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NMD.2021.01.001</ArticleId><ArticleId IdType="pubmed">33451933</ArticleId></ArticleIdList></Reference><Reference><Citation>Amato AA, Sivakumar K, Goyal N, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014;83:2239&#x2013;2246. doi: 10.1212/WNL.0000000000001070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001070</ArticleId><ArticleId IdType="pmc">PMC4277670</ArticleId><ArticleId IdType="pubmed">25381300</ArticleId></ArticleIdList></Reference><Reference><Citation>Amato AA, Hanna MG, Machado PM, et al. Efficacy and safety of bimagrumab in sporadic inclusion body myositis: long-term extension of RESILIENT. Neurology. 2021;96:e1595&#x2013;e1607. doi: 10.1212/WNL.0000000000011626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011626</ArticleId><ArticleId IdType="pmc">PMC8032371</ArticleId><ArticleId IdType="pubmed">33597289</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell C, McMillan HJ, Mah JK, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017;55:458&#x2013;464. doi: 10.1002/MUS.25268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/MUS.25268</ArticleId><ArticleId IdType="pubmed">27462804</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivakumar K, Cochrane TI, Sloth B, et al. Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis. Neurology. 2020;95:e1971&#x2013;e1978. doi: 10.1212/WNL.0000000000010417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010417</ArticleId><ArticleId IdType="pubmed">32690797</ArticleId></ArticleIdList></Reference><Reference><Citation>Lach-Trifilieff E, Minetti GC, Sheppard K, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014;34:606&#x2013;618. doi: 10.1128/MCB.01307-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01307-13</ArticleId><ArticleId IdType="pmc">PMC3911487</ArticleId><ArticleId IdType="pubmed">24298022</ArticleId></ArticleIdList></Reference><Reference><Citation>Latres E, Pangilinan J, Miloscio L, et al. Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet Muscle. 2015 doi: 10.1186/S13395-015-0060-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13395-015-0060-8</ArticleId><ArticleId IdType="pmc">PMC4600334</ArticleId><ArticleId IdType="pubmed">26457176</ArticleId></ArticleIdList></Reference><Reference><Citation>st. Andre M, Johnson M, Bansal PN, , et al. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys. Skelet Muscle. 2017 doi: 10.1186/S13395-017-0141-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13395-017-0141-Y</ArticleId><ArticleId IdType="pmc">PMC5679155</ArticleId><ArticleId IdType="pubmed">29121992</ArticleId></ArticleIdList></Reference><Reference><Citation>Polkey MI, Praestgaard J, Berwick A, et al. Activin type II receptor blockade for treatment of muscle depletion in chronic obstructive pulmonary disease. a randomized trial. Am J Respir Crit Care Med. 2019;199:313&#x2013;320. doi: 10.1164/RCCM.201802-0286OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/RCCM.201802-0286OC</ArticleId><ArticleId IdType="pmc">PMC6363975</ArticleId><ArticleId IdType="pubmed">30095981</ArticleId></ArticleIdList></Reference><Reference><Citation>Man WDC, Natanek SA, Riddoch-Contreras J, et al. Quadriceps myostatin expression in COPD. Eur Respir J. 2010;36:686&#x2013;689. doi: 10.1183/09031936.00032510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00032510</ArticleId><ArticleId IdType="pmc">PMC3039204</ArticleId><ArticleId IdType="pubmed">20930205</ArticleId></ArticleIdList></Reference><Reference><Citation>Pomi&#xe8;s P, Rodriguez J, Blaqui&#xe8;re M, et al. Reduced myotube diameter, atrophic signalling and elevated oxidative stress in cultured satellite cells from COPD patients. J Cell Mol Med. 2015;19:175&#x2013;186. doi: 10.1111/JCMM.12390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/JCMM.12390</ArticleId><ArticleId IdType="pmc">PMC4288361</ArticleId><ArticleId IdType="pubmed">25339614</ArticleId></ArticleIdList></Reference><Reference><Citation>Loumaye A, de Barsy M, Nachit M, et al. Role of activin a and myostatin in human cancer cachexia. J Clin Endocrinol Metab. 2015;100:2030&#x2013;2038. doi: 10.1210/JC.2014-4318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/JC.2014-4318</ArticleId><ArticleId IdType="pubmed">25751105</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatakeyama S, Summermatter S, Jourdain M, et al. ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skelet Muscle. 2016 doi: 10.1186/S13395-016-0098-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13395-016-0098-2</ArticleId><ArticleId IdType="pmc">PMC4960708</ArticleId><ArticleId IdType="pubmed">27462398</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142:531&#x2013;543. doi: 10.1016/J.CELL.2010.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELL.2010.07.011</ArticleId><ArticleId IdType="pubmed">20723755</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RC, Cramer MS, Mitchell PJ, et al. Myostatin neutralization results in preservation of muscle mass and strength in preclinical models of tumor-induced muscle wasting. Mol Cancer Ther. 2015;14:1661&#x2013;1670. doi: 10.1158/1535-7163.MCT-14-0681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-14-0681</ArticleId><ArticleId IdType="pubmed">25908685</ArticleId></ArticleIdList></Reference><Reference><Citation>Kun M, Mallidis C, Artaza J, et al. Characterization of 5&#x2019;-regulatory region of human myostatin gene: regulation by dexamethasone in vitro. Am J Physiol Endocrinol Metab. 2001 doi: 10.1152/AJPENDO.2001.281.6.E1128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/AJPENDO.2001.281.6.E1128</ArticleId><ArticleId IdType="pubmed">11701425</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin J, Du R, Yang YQ, et al. Dexamethasone-induced skeletal muscle atrophy was associated with upregulation of myostatin promoter activity. Res Vet Sci. 2013;94:84&#x2013;89. doi: 10.1016/J.RVSC.2012.07.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.RVSC.2012.07.018</ArticleId><ArticleId IdType="pubmed">22939086</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilson H, Schakman O, Combaret L, et al. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology. 2007;148:452&#x2013;460. doi: 10.1210/EN.2006-0539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/EN.2006-0539</ArticleId><ArticleId IdType="pubmed">17038559</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JD, Hobson R, Chaudhari V, et al. Activin type II receptor signaling in cardiac aging and heart failure. Sci Transl Med. 2019 doi: 10.1126/SCITRANSLMED.AAU8680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCITRANSLMED.AAU8680</ArticleId><ArticleId IdType="pmc">PMC7124007</ArticleId><ArticleId IdType="pubmed">30842316</ArticleId></ArticleIdList></Reference><Reference><Citation>Heineke J, Auger-Messier M, Xu J, et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation. 2010;121:419&#x2013;425. doi: 10.1161/CIRCULATIONAHA.109.882068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.882068</ArticleId><ArticleId IdType="pmc">PMC2823256</ArticleId><ArticleId IdType="pubmed">20065166</ArticleId></ArticleIdList></Reference><Reference><Citation>George I, Bish LT, Kamalakkannan G, et al. Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur J Heart Fail. 2010;12:444&#x2013;453. doi: 10.1093/EURJHF/HFQ039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/EURJHF/HFQ039</ArticleId><ArticleId IdType="pmc">PMC2857990</ArticleId><ArticleId IdType="pubmed">20348550</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooks DS, Laurent D, Praestgaard J, et al. Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy. J Cachexia Sarcopenia Muscle. 2017;8:727&#x2013;734. doi: 10.1002/JCSM.12205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JCSM.12205</ArticleId><ArticleId IdType="pmc">PMC5659065</ArticleId><ArticleId IdType="pubmed">28905498</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooks D, Petricoul O, Praestgaard J, et al. Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort. J Cachexia Sarcopenia Muscle. 2020;11:1525&#x2013;1534. doi: 10.1002/JCSM.12639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JCSM.12639</ArticleId><ArticleId IdType="pmc">PMC7749589</ArticleId><ArticleId IdType="pubmed">33264516</ArticleId></ArticleIdList></Reference><Reference><Citation>Attie KM, Borgstein NG, Yang Y, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013;47:416&#x2013;423. doi: 10.1002/MUS.23539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/MUS.23539</ArticleId><ArticleId IdType="pubmed">23169607</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooks D, Swan T, Goswami B, et al. Bimagrumab vs optimized standard of care for treatment of sarcopenia in community-dwelling older adults: a randomized clinical trial. JAMA Netw Open. 2020;3:e2020836. doi: 10.1001/JAMANETWORKOPEN.2020.20836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMANETWORKOPEN.2020.20836</ArticleId><ArticleId IdType="pmc">PMC7573681</ArticleId><ArticleId IdType="pubmed">33074327</ArticleId></ArticleIdList></Reference><Reference><Citation>Garito T, Roubenoff R, Hompesch M, et al. Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals. Diabetes Obes Metab. 2018;20:94&#x2013;102. doi: 10.1111/DOM.13042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/DOM.13042</ArticleId><ArticleId IdType="pubmed">28643356</ArticleId></ArticleIdList></Reference><Reference><Citation>Padhi D, Higano CS, Shore ND, et al. Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2014;99:E1967&#x2013;E1975. doi: 10.1210/JC.2014-1271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/JC.2014-1271</ArticleId><ArticleId IdType="pubmed">24971661</ArticleId></ArticleIdList></Reference><Reference><Citation>McPherron AC, Lee S-J. Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest. 2002;109:595&#x2013;601. doi: 10.1172/JCI13562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI13562</ArticleId><ArticleId IdType="pmc">PMC150888</ArticleId><ArticleId IdType="pubmed">11877467</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P, Rong H, Gordi T, et al. Translational pharmacokinetic/pharmacodynamic analysis of MYO-029 antibody for muscular dystrophy. Clin Transl Sci. 2016;9:302&#x2013;310. doi: 10.1111/CTS.12420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/CTS.12420</ArticleId><ArticleId IdType="pmc">PMC5351001</ArticleId><ArticleId IdType="pubmed">27700008</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Lee YS, Zimmers TA, et al. Regulation of muscle mass by follistatin and activins. Mol Endocrinol. 2010;24:1998. doi: 10.1210/ME.2010-0127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/ME.2010-0127</ArticleId><ArticleId IdType="pmc">PMC2954636</ArticleId><ArticleId IdType="pubmed">20810712</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ. Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction. J Clin Investig. 2021 doi: 10.1172/JCI148372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI148372</ArticleId><ArticleId IdType="pmc">PMC8087205</ArticleId><ArticleId IdType="pubmed">33938454</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh BT, Cote SM, Meshulam D, et al. Preclinical safety assessment and toxicokinetics of apitegromab, an antibody targeting proforms of myostatin for the treatment of muscle-atrophying disease. Int J Toxicol. 2021;40:322&#x2013;336. doi: 10.1177/10915818211025477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10915818211025477</ArticleId><ArticleId IdType="pmc">PMC8326894</ArticleId><ArticleId IdType="pubmed">34255983</ArticleId></ArticleIdList></Reference><Reference><Citation>Garito T, Zakaria M, Papanicolaou DA, et al. Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clin Endocrinol (Oxf) 2018;88:908&#x2013;919. doi: 10.1111/CEN.13601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/CEN.13601</ArticleId><ArticleId IdType="pubmed">29566437</ArticleId></ArticleIdList></Reference><Reference><Citation>Schang G, Ongaro L, Schultz H, et al. Murine FSH production depends on the activin type II receptors ACVR2A and ACVR2B. Endocrinology. 2020 doi: 10.1210/ENDOCR/BQAA056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/ENDOCR/BQAA056</ArticleId><ArticleId IdType="pmc">PMC7286621</ArticleId><ArticleId IdType="pubmed">32270195</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause S. Insights into muscle degeneration from heritable inclusion body myopathies. Front Aging Neurosc. 2015;7:13. doi: 10.3389/FNAGI.2015.00013/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FNAGI.2015.00013/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC4325924</ArticleId><ArticleId IdType="pubmed">25729363</ArticleId></ArticleIdList></Reference><Reference><Citation>Garatachea N, Luc&#xed;a A. Genes and the ageing muscle: a review on genetic association studies. Age (Dordr) 2013;35:207&#x2013;233. doi: 10.1007/S11357-011-9327-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S11357-011-9327-0</ArticleId><ArticleId IdType="pmc">PMC3543750</ArticleId><ArticleId IdType="pubmed">22037866</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10:615&#x2013;622. doi: 10.1038/nn1876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1876</ArticleId><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips AM, Hester ME, Miranda CJ, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 2011;29:824. doi: 10.1038/NBT.1957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/NBT.1957</ArticleId><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>